Commonwealth Equity Services’s BioLineRX BLRX Stock Holding History

Commonwealth Equity Services’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37	Closed	-$8K	–	2840
2019 Q2	$8K	Hold	37	–	–	﹤0.01%	2763
2019 Q1	$9K	Hold	37	–	–	﹤0.01%	2730
2018 Q4	$9K	Sell	37 -50	-57%	-$24.1K	﹤0.01%	2653
2018 Q3	$55K	Sell	87 -38	-30%	-$20.9K	﹤0.01%	2689
2018 Q2	$67K	Hold	125	–	–	﹤0.01%	2639
2018 Q1	$65K	Buy	125 +33	+36%	+$20.2K	﹤0.01%	2582
2017 Q4	$60K	Hold	92	–	–	﹤0.01%	2554
2017 Q3	$62K	Hold	92	–	–	﹤0.01%	2455
2017 Q2	$46K	Hold	92	–	–	﹤0.01%	2424
2017 Q1	$53K	Hold	92	–	–	﹤0.01%	2319
2016 Q4	$51K	Buy	92 +54	+142%	+$33.5K	﹤0.01%	2240
2016 Q3	$26K	Hold	38	–	–	﹤0.01%	2202
2016 Q2	$18K	Hold	38	–	–	﹤0.01%	2204
2016 Q1	$23K	Hold	38	–	–	﹤0.01%	2164
2015 Q4	$30K	Buy	+38	New	+$31.5K	﹤0.01%	2132

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commonwealth Equity Services's BLRX Position: Q3 2019 in Review

Commonwealth Equity Services sold out of BioLineRX (BLRX) in Q3 2019, closing a stake of 37 shares — an estimated $8K sold.

Commonwealth Equity Services first reported a position in BLRX in Q4 2015 and held it in 15 quarters. The position peaked at $67K in Q2 2018. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2019.

Commonwealth Equity Services reported no remaining BioLineRX position as of Q3 2019 after selling out during the quarter.
Commonwealth Equity Services sold 37 BioLineRX shares in Q3 2019, an estimated $8K.
Commonwealth Equity Services first reported a position in BioLineRX in Q4 2015 and held it in 15 quarters.
Commonwealth Equity Services's BioLineRX position peaked at $67K in Q2 2018.
15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2019.

Based on Commonwealth Equity Services's 13F filing for Q3 2019, filed 30 Oct 2019.